Management is awaiting for St Jude Children's Research Hospital to release the second part of the study of Paxalisib (GDC-0084) in DIPG.
According to management's milestone estimate, the provisional interim data is now due.
Maybe there are negotiations underway, with regards to the ASX RELEASE ON 7 August 2020, US FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION (RPDD)TO PAXALISIB FOR DIPG?
This is the release of the first stage on 12 September 2019.
https://www.prnewswire.com/news-releases/st-jude-study-of-gdc-0084-in-dipg-successfully-completes-first-stage-second-part-of-study-now-underway-300916919.html
Regards.
- Forums
- ASX - By Stock
- KZA
- Across the pond...Nasdaq: KZIA
Across the pond...Nasdaq: KZIA, page-183
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online